fuadelhibri
male - 51 years
Blog 3
-
Jones has $127,000
U.S. Rep. Walter Jones has $127,766 in his campaign account.
According to federal election records, Jones, a Farmville Republican, received $126,667 in individual contributions and $98,430 from political action committees for a total of $225,000 in contributions through September.
Contributors include Fuad El-Hibri of Potomac, Md., chief executive of Emergent Biosolutions ($2,400); Dr. Jasper Lewis Jr., a Greenville dentist ($2,400); the American Academy of Pediatric Dentistry PAC ($5,000) and the American Crystal Sugar PAC ($5,000). -
Emergent BioSolutions Inc. Q3 2009 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS)
Q3 2009 Earnings Call Transcript
November 5, 2009 5:00 pm ET
Executives
Robert Burrows – VP, IR
Fuad El-Hibri – CEO and Chairman
Don Elsey – CFO and SVP, Finance & Administration
Denise Esposito – SVP, Legal Affairs, General Counsel and Secretary
Jim Jackson – SVP and Chief Scientific Officer
Dan Abdun-Nabi – President and COO
Analysts
Eric Schmidt – Cowen & Company
David Moskowitz – Caris & Company
Matt Hussey [ph] – ADR Research [ph]
Daniel Mallin – WBB Securities
Cory Kasimov – JP Morgan
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the third quarter 2009 Emergent BioSolutions Inc. earnings conference call. My name is Chanel, and I will be your operator for today. At this time, all participants are in listen only mode. Later we will conduct a question and answer session. (Operator instructions) As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference over to your host for today's call, Mr. Robert Burrows. Please proceed.
Robert Burrows
Thank you, Chanel. Good afternoon, ladies and gentlemen. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss Emergent BioSolutions financial results for the third quarter and first nine months of 2009. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions.
Joining me on the call this afternoon with prepared comments will be Fuad El-Hibri, Chairman and Chief Executive Officer, and Don Elsey, Chief Financial Officer. Additional members of our senior management team will be present on the call for purposes of the Q&A session.
Before we begin, I am compelled to remind everyone that during the call, management may make projections and other forward-looking statements regarding future events and the company’s prospects or future performance. These forward-looking statements reflect Emergent’s current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements.
You are encouraged to review Emergent’s filings with the SEC on Forms 10-K, 10-Q, and 8-K for more information on the risks and uncertainties that could cause actual results to differ. For the benefit of those who may be listening to the replay, this call was held and recorded on November 5, 2009. Since then, Emergent may have made announcements relating to topics discussed during today’s call, so again, please reference our most recent press releases and SEC filings.
Emergent BioSolutions assumes no obligation to update the information in today’s press release or as presented on this call except as may be required by applicable laws or regulations. Today’s press release may be found on our website at www.emergentbiosolutions.com under Investors/Press Release. And with that introduction, I would now like to turn the call over to Fuad El-Hibri, Emergent BioSolutions' Chairman and CEO. Fuad?
Fuad El-Hibri
Thank you, Bob. Good afternoon, ladies and gentlemen. We appreciate your participation on this call. Today, we reported financial results for the third quarter and first nine months of 2009. I am very pleased with Emergent's overall performance year-to-date. We delivered strong sales and earnings results while continuing to invest in our product pipeline. Based upon our year-to-date performance, we are reaffirming our forecast for total revenues of approximately $225 million to $240 million and net income in excess of $20 million. Let me remind you, as I have done previously, that this forecast does not affect any financial impact from an rPA award or M&A activity. -
CV
Fuad El-Hibri
Chairman of the Board of Directors and Chief Executive Officer
Emergent BioSolutions Inc.
Professional Background
Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia.
Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and distribution of Porton’s biodefense vaccines to foreign governments in the early 1990’s, Mr. El-Hibri organized a management buyout of Porton in 1994, forming Speywood Holdings, Ltd. He was appointed to the Board of Directors of Speywood Holdings, Ltd. and acted as an advisor to the senior management team in the operations of the company until 1996.
Starting in the 1990’s, Mr. El-hibri formed and then sold three mobile telecommunications companies, Mobile TeleSystems, serving the greater Moscow region, as well as Digitel and Digicel, serving markets in South and Central America.
Mr. El-Hibri began his career with Citigroup in commercial banking and subsequently in mergers & acquisitions. Following his tenure at Citigroup, Mr. El-Hibri joined Booz Allen & Hamilton as a management consultant in South East Asia, where he led several large client engagements.
Education
Mr. El-Hibri holds a Masters Degree in public and private management from Yale University, and a Bachelor of Arts Degree in economics from Stanford University.
Community Service and Philanthropy
Mr. El-Hibri is active in a variety of not-for-profit, academic, and other community-based organizations both in the United States and internationally. Mr. El-Hibri is involved in the following organizations:
The American University
Mr. El-Hibri serves on the Board of Trustees of American University (AU), a global institution of higher learning located in Washington, DC. Mr. El-Hibri is also a Founding Donor of an endowment for the Center for Global Peace, a separate non-profit organization within the AU community focused on creating, developing and promoting initiatives for global peace and conflict resolution.
The International Biomedical Research Alliance
Mr. El-Hibri serves on the Board of Trustees of the International Biomedical Research Alliance, an academic joint venture among the U.S. National Institutes of Health, Oxford University and Cambridge University, dedicated to promoting the advancement of excellence in biomedical research. In pursuit of its mission, the Alliance provides philanthropic, scientific and industry resources dedicated to developing the National Institutes of Health/Oxford/Cambridge Biomedical Research Scholars Program, which recruits extraordinarily talented students for a PhD or MD/PhD in biomedical research and prepares them for a lifetime of excellence in scientific exploration and healthcare leadership.
The National Health Museum
Mr. El-Hibri serves on the Board of Trustees of the National Health Museum, a science-based institution with the mission of educating Americans on the subject of health and inspiring them to live healthier lives. The museum plans to build an innovative, educational, media driven facility that will be located in a major metropolitan area in the U.S. for the benefit of national and international visitors.
The Heifetz International Music Institute
Mr. El-Hibri serves as a member of the Advisory Board for the Heifetz Institute, a six-week summer program, founded by acclaimed violinist Daniel Heifetz, dedicated to creating unique programs designed to teach young musicians the art of communicating and expressing themselves through music to audiences worldwide.
The El-Hibri Charitable Foundation
Mr. El-Hibri serves as the Chairman of the El-Hibri Charitable Foundation (ECF), a non profit organization which is dedicated to fostering interfaith collaboration, including the mutual understanding and appreciation among different cultures and religions, and the support of humanitarian programs. The ECF is a major contributor to the orphanage of Dar Al-Aytam in Lebanon, which provides shelter, education and medicine for hundreds of orphans as well as indigent and handicapped members of the society.
Family
Mr. El-Hibri lives in Potomac, Maryland with his wife Nancy. They have three grown children, Karim, Yusra, and Faiza.
